Chronic Pancreatitis, Pancreatic Cysts, and Pancreatic Neoplasms: Chronic Pancreatitis and Cysts: Diagnosis and Pain

0:00Welcome to Board Pearls. This is episode one of five of the Chronic Pancreatitis, Pancreatic Cysts, and Pancreatic Neoplasms chapter, in the Pancreatic and Biliary Disease module. This episode is chronic pancreatitis: the cause, the diagnosis, and the pain. The first patient is a man who drinks and smokes, and his case shows what chronic pancreatitis is and the single finding that proves it, how TIGAR-O organizes the causes, why so few heavy drinkers get it and what smoking adds, the cause never to miss, and who needs genetic testing. The second patient is a young woman with a normal computed tomography, CT, and her case shows how the diagnosis is proved anyway: secretin magnetic resonance cholangiopancreatography, MRCP, endoscopic ultrasound, EUS, and the Rosemont criteria, why endoscopic retrograde cholangiopancreatography, ERCP, isn't used, and what the function tests add and where they mislead. The first man returns a year later on oxycodone every four hours, and his case shows where the pain comes from, what to try first and what to avoid, endoscopy versus surgery for an obstructed duct, and when total pancreatectomy with islet autotransplantation is considered.

1:17Here's the first patient. A forty-nine-year-old man has had epigastric pain on and off for three years, radiating to his back, with two admissions for acute pancreatitis. He's drunk six to eight beers a day for twenty years and smokes a pack and a half a day. Over six months he's lost four kilograms, and his stools are loose and greasy. His CT shows scattered calcifications throughout the pancreas, a dilated, irregular main duct, and gland atrophy. His fasting glucose is one hundred thirty-five.

1:48Recurrent pain, prior attacks, steatorrhea, weight loss, a rising glucose, and pancreatic calcifications on CT add up to chronic pancreatitis. It's a fibroinflammatory syndrome in people with genetic, environmental, or other risk factors who mount a persistent pathologic response to injury or stress in the gland. It ends in acinar atrophy, distorted and strictured ducts, parenchymal calcification, pseudocysts, lost exocrine and endocrine function, and dysplasia: scar replacing the tissue that secretes and drains. His atrophy and irregular duct are the scar, his greasy stools are lost exocrine function, and his glucose is early endocrine loss. Parenchymal calcification is pathognomonic, so his CT makes the diagnosis without a function test or a biopsy. In the United States, prevalence is roughly forty to ninety per hundred thousand, men are affected twice as often as women, and onset peaks at forty-five to fifty-five.

2:48His cause is classified by TIGAR-O, because the cause decides what has to stop and what has to be excluded. The categories are toxic-metabolic, idiopathic, genetic, autoimmune, recurrent and severe acute pancreatitis, and obstructive. Toxic-metabolic is dominated by heavy alcohol, averaging more than four to five drinks a day for years, with an attributable risk of about forty percent, and by tobacco, about twenty-five percent, with hypercalcemia and chronic kidney disease as secondary contributors. Idiopathic includes early-onset, late-onset, and tropical forms. Genetic covers PRSS1, SPINK1, CFTR, CTRC, and CASR. Autoimmune covers type one, related to immunoglobulin G4, and type two, idiopathic duct-centric disease, covered in episode three. Recurrent and severe acute pancreatitis evolves into chronic disease in a minority, as his two admissions did. The M-ANNHEIM scheme grades clinical stage, pain, complications, and exocrine and endocrine function separately, and it's more useful for research than for bedside decisions.

4:01His drinking alone probably didn't do it. Fewer than three percent of heavy drinkers develop chronic pancreatitis, so something has to convert the exposure into fibrosis, and tobacco is the dominant co-factor. Smoking is an independent, dose-dependent risk, with more than a pack a day carrying a hazard ratio of about three, and it may be the strongest driver of progression from acute to chronic disease. Smokers have more atrophy, more pseudocysts, and more pain than non-smokers with the same alcohol exposure. The CLDN2 locus drives the synergy between alcohol and tobacco, so genetic background decides whether the exposure turns into fibrosis. He has both exposures, so stopping both is his first treatment, because giving up beer while still smoking lets his gland keep worsening.

4:50Even with an obvious cause, one cause is never missed, and that's obstruction. Obstructive causes include strictures from prior injury, ampullary tumors, pancreas divisum in genetically predisposed patients, and pancreatic adenocarcinoma causing back-pressure pancreatitis, especially in an older patient with a first unexplained attack. His duct is diffusely irregular rather than cut off, and his weight loss can come from steatorrhea and from eating less to avoid pain, but chronic pancreatitis itself raises the risk of dysplasia, so his history doesn't close the question. A sixty-eight-year-old woman who doesn't drink, with a first attack and a single main duct stricture with upstream dilation, needs a tumor excluded before any other label. Adenocarcinoma is covered in episode five.

5:35Genetic testing is selective, because it only helps when the cause is in doubt. It's indicated when the cause is unclear, when there's a family history of pancreatitis, or when onset is before age thirty-five, because a clear cause changes counseling about the alcohol-tobacco synergy and about cancer, and may lead to surveillance. He meets none of those. The genes differ by mechanism. PRSS1, cationic trypsinogen, with the common variants R122H and N29I, is gain-of-function: the mutated trypsinogen escapes inactivation, and the gland repeatedly digests itself. It's autosomal dominant with about eighty percent penetrance, a median onset at ten to twenty years, and recurrent acute pancreatitis followed by relentless progression.

6:22The other genes are modifiers rather than causes on their own. SPINK1 is a trypsin inhibitor, and its loss-of-function variants remove a brake on trypsin, giving a permissive rather than dominant effect; they're found in about two percent of healthy people, twenty percent of idiopathic chronic pancreatitis, and half of tropical pancreatitis. CFTR variants impair ductal chloride and bicarbonate secretion, so the duct can't flush its own zymogens. Inheritance is recessive, with thousands of described variants, and milder ones cause isolated pancreatitis without full cystic fibrosis. CTRC, chymotrypsin C, inactivates trypsin as a second line of defense, and CASR variants modify calcium-driven trypsinogen activation.

7:11A patient from the last chapter shows what a result means. The thirty-three-year-old woman with two idiopathic attacks, a mother with pancreatitis, and pancreas divisum has a SPINK1 variant, a permissive modifier that lowers her threshold, which makes avoiding alcohol and tobacco even more important for her. A PRSS1 result would have carried a standardized incidence ratio of about fifty-three for pancreatic adenocarcinoma. In a contemporary United States cohort, about seven percent of carriers had died of pancreatic cancer by seventy, which makes PRSS1 the only form of chronic pancreatitis with recommended surveillance, annual magnetic resonance imaging alternating with EUS from age forty, as chapter thirty-six covers. Because it's dominant, each of her children would have a one-in-two chance of inheriting it.

8:01His calcification made his diagnosis easy, and the second patient shows how it's made without it. A thirty-eight-year-old woman had two alcohol-related admissions for acute pancreatitis, three and five years ago, and stopped drinking after the second; she doesn't smoke. For a year she's had daily epigastric pain, worse after meals and boring through to her back, with three or four loose stools a day and a stable weight. Her contrast CT is normal, and her referral letter says chronic pancreatitis has been ruled out.

8:29Her normal CT doesn't rule out chronic pancreatitis, because no single test does. The diagnosis integrates symptoms, structural imaging, and function, because no biomarker is accurate and histology is rarely available. Recurrent acute pancreatitis precedes chronic pancreatitis in about sixty percent, and pain, epigastric, radiating to the back, often after eating, occurs in about eighty-five percent over the course of the disease, so her history keeps suspicion high. About half of patients with painless disease already have exocrine or endocrine dysfunction at presentation, which is why function is tested even without pain.

9:09Her CT was the right first test, but it misses early disease. Contrast CT is first line, with a sensitivity of sixty-five to eighty percent and a specificity of eighty to ninety, because it shows calcification best and separates pancreatic calcification from gastric, duodenal, or splenic vessel calcification. It can be normal in early, minimal-change disease, so her normal CT doesn't exclude it. When suspicion stays high, secretin MRCP distends the duct and fills its side branches, among the earliest ductal changes, which makes it the favored test for minimal-change disease when CT and standard MRCP are normal.

9:50EUS is the other option, and it looks at the gland itself. With a sensitivity of eighty to ninety percent, it uses the Rosemont criteria: parenchymal features, hyperechoic foci with shadowing, hyperechoic strands, lobulation, and cysts, and ductal features, hyperechoic margins of the main duct, an irregular main duct, dilated side branches, and intraductal calcifications. These grade the gland as consistent with, suggestive of, or indeterminate for chronic pancreatitis, or normal. EUS shows the parenchyma without injecting the duct, but agreement between observers is modest, and age alone causes changes. Her EUS shows strands, lobulation, and a few dilated side branches, without shadowing foci or ductal calcification, which is suggestive. The same mild findings in a seventy-four-year-old without a history might simply be aging.

10:43ERCP isn't her next step, because its risk is highest in patients like her. ERCP with the Cambridge classification is rarely used for diagnosis now, because post-ERCP pancreatitis occurs in three to ten percent overall and up to twenty-five percent in high-risk patients, including young women with a normal bilirubin, and observers disagree in reading it. ERCP is reserved for therapy.

11:08Function testing complements imaging, but it doesn't establish the diagnosis alone. Fecal elastase, the most available exocrine test, has a sensitivity of about sixty percent and a specificity of about eighty-five. A cutoff below one hundred micrograms per gram is more specific, while below two hundred has many false positives in diarrhea, because water dilutes the stool. So her elastase of one hundred sixty, measured in loose stool, is weak evidence, while sixty would have been reliable. The seventy-two-hour fecal fat collection is the gold standard for steatorrhea but is cumbersome and confounded by mucosal disease, gastroparesis, and rapid transit.

11:46The most sensitive test for early disease measures the duct's response to secretin. Secretin-stimulated endoscopic pancreatic function testing works because secretin drives ductal bicarbonate output, and a peak bicarbonate of eighty milliequivalents per liter or more has a high negative predictive value. Hers peaks at fifty-eight. With her two attacks, classic pain, suggestive EUS, and a failed secretin test, she has early chronic pancreatitis. A peak of ninety would have argued strongly against it. The forty-nine-year-old man needs no proof of his disease, but a fecal elastase below one hundred confirms his exocrine insufficiency before he starts enzymes.

12:26The first patient comes back a year later with pain that's now his main problem. His main duct is nine millimeters, with an eight-millimeter stone in the head and upstream dilation. His pain is constant, he's been admitted four times this year, and he takes oxycodone every four hours. He's cut down to two beers a day and still smokes. He asks for something stronger.

12:47He has painful chronic pancreatitis with a dilated, obstructed duct, and treating his pain starts with where it comes from. Pain in chronic pancreatitis has several sources: inflammation of the gland, fluid collections, obstruction by a stone, stricture, or mass affecting the bile duct, the pancreatic duct, or the duodenum, and neural sensitization with central reorganization of pain. He has at least obstruction and sensitization. Pain correlates poorly with imaging, so a normal-looking gland doesn't exclude debilitating pain, and calcification doesn't guarantee it. Alcohol-related disease is more painful than other causes, pain doesn't depend on disease duration, about forty percent of patients with constant pain are admitted more than three times a year, and no reliable predictor identifies who will respond to intervention. The woman's daily pain with a near-normal CT is just as real.

13:41Something stronger isn't his answer; medical management is. It starts with stopping alcohol and tobacco, which sustain the fibroinflammatory process. Acetaminophen and nonsteroidal anti-inflammatory drugs are first line, supplemented by neuromodulators for sensitization: gabapentin or pregabalin, a tricyclic, a selective serotonin reuptake inhibitor, or a serotonin-norepinephrine reuptake inhibitor, with pregabalin effective in a randomized trial. Opioids are minimized, because they cause dependence, induce central sensitization, and cause dysmotility, so his oxycodone isn't increased; he adds pregabalin and scheduled acetaminophen with a plan to taper.

14:21Other medical options help less. Pancreatic enzyme replacement has a small effect on pain, because lipolysis in the duodenum feeds back to reduce cholecystokinin-driven stimulation of the gland, so it's used when exocrine insufficiency coexists, as his does, rather than as primary pain therapy. The evidence for antioxidants is mixed. An EUS-guided celiac plexus block helps about half of patients, for a limited time, because it blocks visceral afferent signals without treating the source of the pain.

14:52His obstructed duct can be decompressed, endoscopically or surgically. Endoscopic decompression means pancreatic sphincterotomy, dilation and stenting of strictures, and extracorporeal shock-wave lithotripsy for stones larger than five millimeters, which gives immediate improvement in about three-quarters of patients but long-term relief in only about half. Surgical drainage means a lateral pancreaticojejunostomy, the modified Puestow operation, or sometimes a head resection that preserves the duodenum. In a randomized trial in dilated-duct disease, early surgery gave more durable pain relief than an endoscopy-first approach, sustained at five years, and about half of the endoscopy-first group needed surgery anyway. That's because surgery decompresses the whole dilated duct in one operation, while endoscopy relieves a focal point.

15:40His duct and his pain point to surgery. With a nine-millimeter duct and uncontrolled constant pain, he's referred for early lateral pancreaticojejunostomy. Endoscopy with lithotripsy for his stone would suit a patient who isn't fit for surgery or declines it, with the warning that relief lasts in only about half. A symptomatic pseudocyst would be drained first, usually by EUS with a lumen-apposing metal stent, as episode two covers.

16:08The last option is total pancreatectomy with islet autotransplantation, and it's reserved for a narrow group. The thirty-eight-year-old woman has no dilated duct or stone, so neither lithotripsy nor surgical drainage fits her, and her treatment is medical, with acetaminophen and pregabalin and no opioids. Total pancreatectomy with islet autotransplantation is reserved for hereditary or small-duct chronic pancreatitis with intractable pain after endoscopic and standard surgical options fail. Islet yield tracks how much function remains before surgery, so operating early in PRSS1 disease, before fibrosis destroys the islets, gives better long-term insulin independence. Even then, insulin independence declines over time, patients have type three c diabetes afterward, and pain can persist from central sensitization and dysmotility, so selection is strict. She isn't a candidate, while a patient with PRSS1 and relentless attacks would be considered early.

17:09Here are the traps the boards set in cause and genetics. Calcification proves the diagnosis without a function test. Stopping alcohol isn't enough while the patient still smokes. An older patient with a first unexplained attack needs an obstructing cancer excluded. Genes aren't tested when the cause is obvious, but they are in a young patient with a family history. SPINK1 is a permissive modifier, not a dominant gene. And PRSS1 is the only form that brings cancer surveillance.

17:38For diagnosis, the traps are these. A normal CT doesn't rule out chronic pancreatitis. ERCP isn't used to diagnose it. Mild EUS changes in an older patient may be aging. Secretin enhances MRCP for early disease. A fecal elastase between one hundred and two hundred in watery stool isn't reliable. Fecal fat isn't specific for pancreatic disease. And secretin function testing can detect disease while imaging is normal.

18:08For pain, the traps are these. Pain isn't judged by the scan. A neuromodulator is added rather than more opioid. Enzymes aren't primary pain therapy. A celiac plexus block doesn't last. A fit patient with a dilated duct gets early surgery rather than repeated endoscopy. Lithotripsy is for stones over five millimeters. And total pancreatectomy with islet autotransplantation isn't offered before other options fail, but in hereditary disease it isn't delayed until the islets are gone.

18:40So, start to finish. Chronic pancreatitis ends in atrophy, ductal distortion, calcification, and lost function, and calcification is pathognomonic. Classify the cause by TIGAR-O: alcohol and tobacco dominate, smoking independently speeds progression, and an obstructing cancer is always considered. Test genes for young onset, a family history, or no clear cause, and remember that PRSS1 alone brings surveillance from forty.

19:10Start with contrast CT, then secretin MRCP or EUS when suspicion stays high, without diagnostic ERCP. A fecal elastase below one hundred is more specific, it's falsely low in watery stool, and secretin function testing is the most sensitive test for early disease.

19:30Treat pain by stopping alcohol and tobacco, using acetaminophen, anti-inflammatories, and pregabalin, and minimizing opioids. Drain a dilated, obstructed duct surgically and early, with endoscopy and lithotripsy for stones over five millimeters when surgery isn't chosen, and reserve total pancreatectomy with islet autotransplantation for intractable hereditary or small-duct disease, done early in PRSS1.

19:58Episode two is what the scarred gland stops making, enzyme replacement and type three c diabetes, and the complications of chronic pancreatitis.

20:09For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode one of five of chapter twenty-six, and I'll see you in the next one.